The strongest pharmacogenetic evidence in medicine is in your prescription pad.
CYP2D6 and CYP2C19 carry CPIC Level A guidance for SSRIs and tricyclics — the most actionable drug–gene pairs that exist. This is the panel that tells you which of them your patient is, before the third failed trial.
Buy ten or more of any SKU and we match it, free, until your next order.
Shown on the Pharmacogenetics (PGX) panel. Every panel in the catalogue works the same way.
Trial-and-error is the current standard. That is the opportunity.
No other specialty has a gap this wide between what the evidence supports and what is routinely ordered.
For CYP2D6 and CYP2C19 with multiple antidepressants — the strongest actionable tier there is.
There is no re-test. We will not sell a subscription against a result that cannot change.
Your opening order, yours once bought.
It does not predict whether a drug will work, and it does not choose the drug. It describes metabolism — how fast a patient clears a compound — which is one input into a prescribing decision you make. Any vendor telling you a PGX panel predicts antidepressant response is selling something the evidence does not support.
Start with one. Stack the second.
We recommend a lead panel from your patient mix rather than from our margin. These are the two that fit this room.
Psychiatry is where pharmacogenetics has its strongest and least contested case: CYP2D6 and CYP2C19 metabolizer status has CPIC Level A guidance for multiple antidepressants, and the alternative is trial-and-error across weeks-long titrations. It is a swab, it is answered once, and it is the panel your patients are most likely to have already read about.
It does not predict whether a drug will work. It describes metabolism, which is one input into a prescribing decision you make.
Patients on second-generation antipsychotics need metabolic monitoring — weight, lipids, glucose. This is that panel, and it is a cash-pay product rather than an argument with a payer about frequency.
It is not a TRT diagnostic on its own. Men's health clinics should ask about the reconfigured TRT Baseline build, which adds PSA, LH, FSH, SHBG, calculated free testosterone and reflexed prolactin.
Every panel ships on the same terms. Adding one adds a revenue line without adding capital, space or chair time. The full catalogue is here.
You buy it. You price it. You keep the difference.
Populate the table with your own volume — these are our assumptions, not your numbers.
| New starts / month | Panels / month | You keep each | Monthly | Annual |
|---|---|---|---|---|
| 10 new patients | 10 | $75 | $750 | $9,000 |
| 25 new patients | 25 | $75 | $1,875 | $22,500 |
| 50 new patients | 50 | $75 | $3,750 | $45,000 |
One panel per new patient at intake, at the PGX margin. PGX is the thinnest margin in the catalogue by design — it is the panel that earns the relationship, and the General Wellness line is where the economics sit.
Baseline. Treat. Prove it moved.
The panel is what makes everything else you sell repeatable, and it creates a second high-value visit per cycle.
Baseline
A panel establishes status before anything is prescribed.
Visit oneIntervention
Your protocol as today, plus whatever the panel indicated. That decision is yours, not ours.
Your protocolRe-test when indicated
A clinically indicated re-test shows what moved — and gives the patient a reason to come back and see it.
Visit twoShow the patient what it is
Two clips per panel, sized for a waiting-room screen or a social post. Download them from the poster page along with the print files.
What the Pharmacogenetics (PGX) panel measures and how the sample is collected.
What the General Wellness panel measures and how the sample is collected.
A poster for the waiting room.
Typeset, not AI-generated — so the text is correct and the claims match the standards page. A4 and US Letter for print, plus a square crop for social.
Your practice name can be added to the footer of any poster — send it with your application and we will supply a personalised set.
What you will ask first
Including the ones where the honest answer costs us the sale.
Is there outcome evidence for PGX-guided prescribing?
It is mixed, and you should know that before you buy. The evidence for metabolizer status affecting drug exposure is strong and CPIC-graded; the evidence that genotype-guided prescribing improves remission rates is contested. We sell the first claim, not the second.
Will insurance cover it?
Sometimes, and inconsistently. This is a cash-pay product and we do not model it any other way. If your patient has coverage for PGX through another route, that is usually the better path for them.
Which pairs are actually actionable?
CYP2D6 and CYP2C19 with several SSRIs and tricyclics carry CPIC Level A. We will send the current pair list with the assay methods before you order rather than describing it in marketing copy.
Does a result change my prescribing today?
Sometimes not at all — a normal metabolizer result changes nothing, and that is a legitimate outcome worth paying for. The value is concentrated in the poor and ultrarapid metabolizers, and you cannot know which patient that is without testing.
What arrives
- Your opening order — buy ten or more and we match it
- One virtual training session for your team
- Provider portal access for results
- The CLIA certificate number and named assay methods
- Print-ready posters and the waiting-room video files
Panels are laboratory-developed tests performed by a CLIA-certified laboratory. They are not FDA-cleared for the indications described and do not diagnose, stage or grade disease. Economics shown are illustrative and not a guarantee of results.